|
|
|
|
third-line therapy
Treatment that is given when both initial treatment (first-line therapy) and subsequent treatment (second-line therapy) don’t work, or stop working. (National Cancer Institute)
Public Citizen: Petition to the FDA to Remove the Cancer Drug ... Mar 4, 2005
...approval for the treatment of non-small cell lung cancer (NSCLC) in patients who had failed at least two other treatment regimens (third-line therapy). ... PharmaLive.com (press release),
Pro-Pharmaceuticals and Medidata Solutions Team Up to Implement ... Mar 14, 2005
...initiated a Phase II clinical trial to evaluate efficacy and safety of DAVANAT/5-FU when administered in monthly cycles as a third-line therapy for metastatic ... Yahoo News (press release)
Chasing Mutations in the Epidermal Growth Factor in Lung Cancer Feb 23, 2005
...kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), have been approved in the United States for use as second-line or third-line therapy in advanced ... New England Journal of Medicine (subscription),
Blood test for cancer Feb 26, 2005
It is used for treatment of patients both as first-line therapy in combination with paclitaxel and as a single agent in second and third-line therapy. ... News 8 Austin,
Pro-Pharmaceuticals' Final Phase I Abstract Accepted for ... Mar 3, 2005
...that is intended to evaluate the efficacy and safety of intravenous DAVANAT(R)/5-FU when administered in monthly cycles as a third-line therapy for metastatic ... Business Wire (press release),
Pro-Pharmaceuticals Engages WorldCare Clinical to Enhance and ... Feb 24, 2005
...with 5-FU that will evaluate the efficacy and safety of intravenous DAVANAT/5-FU when administered in monthly cycles as a third-line therapy for metastatic ... Business Wire (press release),
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Targeting Targeted Therapy May 19, 2004
In May 2003, the orally administered EGFR inhibitor gefitinib was approved by the Food and Drug Administration as third-line therapy for non–small-cell lung ... New England Journal of Medicine (subscription)
Resources from the National Cancer Institute on third-line therapy:
|
|
|
